Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582191 · ClinicalTrials.gov registry record · Phase 1
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
NCT01582191: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01582191 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 151 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582191, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Everolimus
- OTHER Pharmacological Study
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2012-05-14 |
| Est. Completion | 2025-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582191
The ClinicalTrials.gov registry entry for NCT01582191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01582191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582191 about?
NCT01582191 is a clinical study titled "Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer". This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growt...
What is the current status of trial NCT01582191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2012-05-14. Estimated completion is 2025-10-22.
What interventions are being tested in trial NCT01582191?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Everolimus (DRUG), Pharmacological Study (OTHER), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT01582191?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.